
Colinz Laboratories Ltd: Valuation Shift Signals Renewed Price Attractiveness
2026-11-05 08:01:45Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, reflecting evolving investor perceptions amid a mixed performance backdrop. This recalibration comes as the company’s price-to-earnings (P/E) ratio moderates to 35.05, aligning more closely with sector peers, while price-to-book value (P/BV) stands at 1.73, signalling a more balanced price attractiveness compared to historical levels.
Read More
Colinz Laboratories Ltd Valuation Shifts Signal Growing Price Pressure
2026-10-30 08:01:44Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift notably towards an expensive zone, reflecting a significant change in market perception. Despite this, the company’s stock has delivered robust returns over multiple time frames, outperforming the Sensex by a wide margin.
Read More
Colinz Laboratories Ltd Valuation Shifts Signal Improved Price Attractiveness
2026-10-22 08:01:00Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its robust returns over multiple time horizons, invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks.
Read More
Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-10-14 08:00:37Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This transition reflects evolving market perceptions amid robust stock performance and changing fundamentals, prompting a downgrade in its Mojo Grade from Hold to Sell as of 19 June 2026.
Read More
Colinz Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-09-03 08:00:55Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market sentiment amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside a broader assessment of its financial health and peer comparisons.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
31-Oct-2026 | Source : BSEDear sir
Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.
29-Oct-2026 | Source : BSEThe Attached Results for Quarter ended on 30-9-2026 was approved in Bopard Meeting held on 29-10-2026 as required under Regulation 30 and 33 and our Auditors have issued Limited Review Report on the same.
Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.
29-Oct-2026 | Source : BSEWe would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 29th October 2026 has inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September 2026.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available